Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update

In this mid-trial update on the use of baricitinib for treating frontal fibrosing alopecia (FFA), a 36-week open-label study involving 15 post-menopausal women with biopsy-proven FFA showed promising results after 12 weeks. The Lichen Planopilaris Activity Index (LPPAI) significantly decreased from 6.18 to 2.26, indicating clinical improvement in disease activity. Patient-reported outcomes for scalp hair growth improved, while eyebrow growth did not show a change. Although the pruritis score decreased, it was not statistically significant. These findings suggest baricitinib may be an effective monotherapy for FFA, but further time is needed to evaluate long-term hair growth and disease remission.